Research programme: epothilone therapeutics - Abraxis/Scripps Research Institute

Drug Profile

Research programme: epothilone therapeutics - Abraxis/Scripps Research Institute

Latest Information Update: 27 Oct 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator The Scripps Research Institute
  • Developer Abraxis BioScience
  • Class Epothilones
  • Mechanism of Action Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 31 Dec 2009 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 23 Aug 2007 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top